Navigation Links
UCLA launches $20 million stem cell institute to investigate HIV, cancer and neurological disorders

Experts in bioengineering, imaging, molecular genetics, immunology, ethics, hematology/oncology and cellular biology to collaborate on Proposition 71 research

Drawing together experts from fields as diverse as engineering to molecular biology, UCLA officials announced March 16 the formation of the Institute for Stem Cell Biology and Medicine to conduct embryonic and adult stem cell research that may lead to better treatments for HIV, cancer and neurological disorders.

"As one of the world's leading research universities, UCLA has long been engaged in adult and embryonic stem cell research with activities in areas ranging from the AIDS Institute to the Brain Research Institute to the UCLA College," said UCLA Chancellor Albert Carnesale. "The new UCLA Institute for Stem Cell Biology and Medicine will enable us to continue fostering such interdisciplinary collaborations and to build upon the existing body of knowledge for the benefit of people worldwide."

UCLA will provide $20 million over five years to launch the campuswide institute, which will enable teams of researchers to compete for state grants created by the passage of Proposition 71. The money will pay for recruitment for a dozen new faculty positions, salaries and expansion of highly sophisticated laboratory space, infrastructure, and supplies.

Dr. Owen Witte, a renowned scientist whose laboratory research laid the groundwork for development of the targeted leukemia therapy Gleevec, is director of the new institute. He also stressed the interdisciplinary approach necessary to face the challenges related to stem cell research. "Embryonic stem cells have the power to develop into every type of human tissue," said Witte, who also is a professor of microbiology, immunology and molecular genetics, and a Howard Hughes Medical Institute investigator. "If we can learn how they are regulated for growth and development, we can harness this knowledge to study tissue development and regener
'"/>

Source:University of California - Los Angeles


Page: 1 2 3 4

Related biology news :

1. UNC launches study of liver injury caused by drugs
2. DOE JGI launches IMG public online microbial genome data clearinghouse
3. NIEHS launches website with information for assessing environmental hazards from Hurricane Katrina
4. NIH launches comprehensive effort to explore cancer genomics
5. Virginia Bioinformatics Institutes launches microbial database
6. BioMed Central launches Biology Direct
7. Protein structure initiative launches new resources for the scientific community
8. NIH neuroscience microarray consortium launches high-throughput genotyping services
9. UW launches study testing adult stem cells for heart damage repair
10. ESA launches new project to protect biodiversity
11. Africas first large-scale HIV vaccine study launches
Post Your Comments:
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. ... molecular diagnostics, today announced the launch of a ... Company,s Precision Cancer Monitoring℠ (PCM) technology for predicting ... one or a combination of the novel immunotherapy ... (nivolumab), a PD-1 inhibitor. The 50-patient study will ...
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
(Date:6/29/2015)... 2015 Research and Markets( ... "Latin America Biomedical Sensors Market - Growth, Trends & ... The Latin America Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2
... nitrogen from Arctic mushrooms to plants is shedding light ... vital nutrients to their hosts. The analytical technique, developed ... of the laboratory's Ecosystems Center and his son, Erik ... be applied to nearly all conifers, oaks, beeches, birch ...
... possible, thanks to a discovery made by a team of ... new stroke death channel ?the conduit through which key chemicals ... death that disables stroke victims. , The findings were ... an editorial in next month's issue of Nature Reviews Neuroscience. ...
... Quebec's first successful combined heart/liver transplant. The patient, Patrice ... de cardiologie de Quebec (l'hôpital Laval) to the MUHC. ... a 6-hour operation on April 14, 2006 and was ... physicians, surgeons and other health care professionals. The MUHC ...
Cached Biology News:New method confirms importance of fungi in Arctic nitrogen cycle 2UBC researchers find stroke death channel 2MUHC announces a transplant first in Quebec 2
(Date:7/28/2015)... , July 28, 2015 Seahorse Bioscience, ... metabolism, is the provider of XF Technology which ... disease research areas. As the links between mitochondrial ... cell metabolism is escalating rapidly.   ... the Nature Publishing Group (NPG) featuring XF Technology, ...
(Date:7/28/2015)... ... ... VetStem Biopharma will be offering weekly private guided tours of our new facility, ... tour and course will be given every Wednesday at 6pm to local interested veterinarians ... are welcome to attend with their veterinarian as well. Participants will be able to ...
(Date:7/28/2015)... July 28, 2015  Moerae Matrix Inc. announced ... clinical trial with MMI-0100, a first-in-class inhibitor of ... for pulmonary disorders characterized by inflammation and fibrosis.  ... Kingdom , is a double-blind, two-way cross-over ... safety and tolerability of MMI-0100 when given via ...
(Date:7/28/2015)... N.C., July 28, 2015  United Therapeutics Corporation (NASDAQ: ... for the second quarter ended June 30, 2015. ... compared to the second quarter of 2014 when ... Ph.D., United Therapeutics, President and Co-Chief Executive Officer. ... an increase in the number of patients being ...
Breaking Biology Technology:XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11
... , , , , ... CTIC) management will present at BioCentury,s NewsMakers in the Biotech Industry conference ... The conference will be held September 16, 2009, at the ... live with slides and available for replay after the presentation. The webcast ...
... CORDOVA, Calif., Sept. 9 ThermoGenesis Corp. (Nasdaq: KOOL ... adult stem cells, today reported results for the fourth quarter and ... quarter ended June 30, 2009, the Company reported revenues of $4.0 ... quarter a year ago. As the Company indicated previously, revenues in ...
... PHILADELPHIA, Sept. 9 GlaxoSmithKline (NYSE: GSK ... (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted ... CERVARIX((R)), the company,s candidate cervical cancer vaccine (12-1 and 11-1, ... be highly effective and well tolerated in girls and young ...
Cached Biology Technology:ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 2ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 3ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 4ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 5ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 6ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 7ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 8ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 9ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 10FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKline's Candidate Cervical Cancer Vaccine 2FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKline's Candidate Cervical Cancer Vaccine 3FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKline's Candidate Cervical Cancer Vaccine 4
... solution has effect on enhancing an antigen-antibody ... than the one obtained by conventional methods. ... antibody used and exposure time in fluorescence/luminescence ... with high S/N ratio and low background. ...
AVOID FREEZE/THAW CYCLES. Recognizes the UCP-2 protein....
... is involved in translation initiation. PHAS-II is ... bind to eIF-4E, the mRNA cap-binding protein, ... vitro and in cells. Phosphorylation in the ... This allows eIF-4E to bind to eIF-4G ...
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
Biology Products: